Waltham, MA-based Proteon Therapeutics, a developer of drugs for kidney and vascular disease, has brought in another $15.2 million in equity- and options-based funding from 19 investors, an SEC filing shows. The biotech company’s last financing was in 2009, when it announced raising $12 million from new backers Bessemer Venture Partners and Devon Park Bioventures to bring its then-funding round to $50 million.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
